For biliary tract cancers, combining Treg-targeted therapies with checkpoint inhibitors like anti-PD1/PDL1 may enhance antitumor effects by counteracting Treg suppression and amplifying effector T cell activity. Here, CD274 is linked to biliary tract cancer.